Someone asked me about Novavax a few days ago. Hop
Post# of 147874
Quote:
Where Novavax could be successful is because of lower cost. Which would lead to widespread use. There's also a niche marketplace in those who are reluctant to take mRNA vaccines. It could easily be $2+ billion in earnings. With $6 billion market cap it's on the low end. The current share price is on the low end of potential.